Brokerages Set AMAG Pharmaceuticals, Inc. (AMAG) Target Price at $20.21

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $20.21.

A number of research analysts have weighed in on AMAG shares. ValuEngine lowered shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 15th. B. Riley set a $21.00 price target on shares of AMAG Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 16th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. BidaskClub raised shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 5th. Finally, SunTrust Banks started coverage on shares of AMAG Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “hold” rating on the stock.

Hedge funds have recently made changes to their positions in the company. California Public Employees Retirement System raised its position in AMAG Pharmaceuticals by 0.8% during the fourth quarter. California Public Employees Retirement System now owns 86,987 shares of the specialty pharmaceutical company’s stock worth $1,321,000 after acquiring an additional 690 shares in the last quarter. Texas Permanent School Fund increased its holdings in shares of AMAG Pharmaceuticals by 4.2% in the fourth quarter. Texas Permanent School Fund now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 909 shares during the last quarter. Strs Ohio increased its holdings in shares of AMAG Pharmaceuticals by 4.2% in the fourth quarter. Strs Ohio now owns 39,500 shares of the specialty pharmaceutical company’s stock valued at $600,000 after purchasing an additional 1,600 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of AMAG Pharmaceuticals by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock valued at $4,334,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Teachers Advisors LLC increased its holdings in shares of AMAG Pharmaceuticals by 0.4% in the third quarter. Teachers Advisors LLC now owns 440,955 shares of the specialty pharmaceutical company’s stock valued at $8,819,000 after purchasing an additional 1,709 shares during the last quarter.

AMAG traded down $0.01 during trading on Thursday, reaching $12.84. The company had a trading volume of 6,525 shares, compared to its average volume of 1,085,351. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.01 and a current ratio of 3.17. AMAG Pharmaceuticals has a 12 month low of $10.70 and a 12 month high of $26.10. The firm has a market cap of $448.45 million, a P/E ratio of -3.34 and a beta of 0.42.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.38. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. The firm had revenue of $88.10 million for the quarter, compared to analyst estimates of $95.21 million. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The business’s revenue was down 31.4% on a year-over-year basis. On average, sell-side analysts anticipate that AMAG Pharmaceuticals will post -3.2 earnings per share for the current fiscal year.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Article: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.